Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation
and modeling software for pharmaceutical discovery and development,
today announced that its board of directors has declared its next
ongoing quarterly cash dividend of $0.05 per share to its shareholders.
This cash dividend will be distributed on Friday, November 14, 2014, for
shareholders of record as of Friday, November 7, 2014.
Mr. John Kneisel, chief financial officer of Simulations Plus, said:
“The Company continues to show excellent financial performance. This
dividend declaration is a continuation of the Board’s plan to continue
its $0.05 per share per quarter dividend distribution. Our consolidated
cash as of today is about $6.6 million, consolidated accounts receivable
is about $2.3 million, and consolidated accounts payable is about
$60,000. This dividend distribution will use about $842,000.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus,
added: “The Board of Directors has once again demonstrated that it
believes in rewarding our loyal shareholders by returning a portion of
our excess cash in the form of dividends. Of course, the board always
has the discretion of discontinuing, increasing, or decreasing the
dividend in accordance with the cash needs of the business.”
About Simulations Plus, Inc. and Cognigen Corp.
Simulations Plus, Inc., is a premier developer of groundbreaking drug
discovery and development simulation and modeling software which is
licensed to and used in the conduct of drug research by major
pharmaceutical, biotechnology, agrochemical, and food industry companies
worldwide. Simulations Plus also recently acquired Cognigen
Corporation of Buffalo, NY, adding top-quality clinical trial data
analysis to our offerings, as well as more than doubling our staff from
30 to 65, adding nearly 50% to revenues, and expecting to increase
earnings in the coming fiscal year that began September 1. The Company
is headquartered in Southern California and trades on the NASDAQ Capital
Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New
York. For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995 – With the exception of historical information, the
matters discussed in this press release are forward-looking statements
that involve a number of risks and uncertainties. Words like “believe,”
“expect” and “anticipate” mean that these are our best estimates as of
this writing, but that there can be no assurances that expected or
anticipated results or events will actually take place, so our actual
future results could differ significantly from those statements. Factors
that could cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the pharmaceutical
industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to
identify and close acquisitions on terms favorable to the Company, and a
sustainable market. Further information on our risk factors is contained
in our quarterly and annual reports as filed with the U.S. Securities
and Exchange Commission.
Copyright Business Wire 2014